JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of federal securities laws during the defined class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Jasper securities between November 30, 2023, and July 3, 2025 [2]. Case Details - The Complaint alleges that Jasper made materially false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - Heightened likelihood of disruptive cost-reduction measures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Defendants' statements regarding the Company's operations and prospects were materially false and misleading [3]. Next Steps - Interested parties can review the Complaint and have until November 18, 2025, to request appointment as lead plaintiff [4]. Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].